Inventor · disambiguated record
Reijo Laaksonen
Also filed as: LAAKSONEN REIJO
27 granted patents·10 pending applications·67 citations·filing 1992–2025
94Inventor score
Top patents by PatentIndex Score
37 records- 0189US12025623B2Lipidomic biomarkers for atherosclerosis and cardiovascular diseaseZORA BIOSCIENCES OY·Filed 2019·Granted Jul 2, 2024·2 cites·23 claims
- 0289US9347960B2Ceramides and their use in diagnosing CVDZORA BIOSCIENCES OY·Filed 2015·Granted May 24, 2016·3 cites·35 claims
- 0388US2024385201A1Lipidomic biomarkers for atherosclerosis and cardiovascular diseaseZORA BIOSCIENCES OY·Filed 2024·Application pending·0 cites
- 0488US2024183866A1Ceramides and their use in diagnosing cvdZORA BIOSCIENCES OY·Filed 2024·Application pending·0 cites
- 0587US10197582B2Ceramides and their use in diagnosing CVDZORA BIOSCIENCES OY·Filed 2016·Granted Feb 5, 2019·2 cites·14 claims
- 0683US9046538B2Lipidomic biomarkers for atherosclerosis and cardiovascular diseaseLAAKSONEN REIJO·Filed 2011·Granted Jun 2, 2015·8 cites·15 claims
- 0782US2025355006A1Biomarkers for cardiovascular eventsZORA BIOSCIENCES OY·Filed 2025·Application pending·0 cites
- 0881US11940453B2Ceramides and their use in diagnosing CVDZORA BIOSCIENCES OY·Filed 2022·Granted Mar 26, 2024·0 cites·18 claims
- 0981US10551394B2Lipidomic biomarkers for atherosclerosis and cardiovascular diseaseZORA BIOSCIENCES OY·Filed 2017·Granted Feb 4, 2020·2 cites·26 claims
- 1075US12270816B2Lipidomic biomarkers for identification of high-risk coronary artery disease patientsZORA BIOSCIENCES OY·Filed 2021·Granted Apr 8, 2025·0 cites·14 claims
- 1175US6555821B1Method for analysis of expired gasWALLAC OY·Filed 2000·Granted Apr 29, 2003·24 cites·14 claims
- 1271US11474116B2Ceramides and their use in diagnosing CVDZORA BIOSCIENCES OY·Filed 2018·Granted Oct 18, 2022·0 cites·11 claims
- 1371US10955427B2Lipidomic biomarkers for identification of high-risk coronary artery disease patientsZORA BIOSCIENCES OY·Filed 2019·Granted Mar 23, 2021·0 cites·30 claims
- 1471US2025264481A1Methods for prediction and early detection of diabetesZORA BIOSCIENCES OY·Filed 2025·Application pending·0 cites
- 1570US12399188B2Biomarkers for cardiovascular eventsZORA BIOSCIENCES OY·Filed 2019·Granted Aug 26, 2025·0 cites·17 claims
- 1670US9201080B2Lipidomic biomarkers for identification of high-risk coronary artery disease patientsLAAKSONEN REIJO·Filed 2011·Granted Dec 1, 2015·1 cites·18 claims
- 1769US9052328B2Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatmentZORA BIOSCIENCES OY·Filed 2012·Granted Jun 9, 2015·1 cites·15 claims
- 1869US9052327B2Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatmentZORA BIOSCIENCES OY·Filed 2012·Granted Jun 9, 2015·1 cites·15 claims
- 1967US9541565B2Biomarkers for sensitive detection of statin-induced muscle toxicityLAAKSONEN REIJO·Filed 2011·Granted Jan 10, 2017·1 cites·20 claims
- 2064US9664698B2Biomarkers for sensitive detection of statin-induced muscle toxicityLAAKSONEN REIJO·Filed 2011·Granted May 30, 2017·1 cites·15 claims
- 2161US9863965B2Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatmentZORA BIOSCIENCES OY·Filed 2016·Granted Jan 9, 2018·0 cites·30 claims
- 2260US10261101B2Lipidomic biomarkers for identification of high-risk coronary artery disease patientsZORA BIOSCIENCES OY·Filed 2017·Granted Apr 16, 2019·0 cites·21 claims
- 2359US9857386B2Lipidomic biomarkers for atherosclerosis and cardiovascular diseaseZORA BIOSCIENCES OY·Filed 2016·Granted Jan 2, 2018·0 cites·25 claims
- 2459US9423406B2Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatmentZORA BIOSCIENCES OY·Filed 2015·Granted Aug 23, 2016·0 cites·18 claims
- 2558US12313634B2Methods for prediction and early detection of diabetesZORA BIOSCIENCES OY·Filed 2018·Granted May 27, 2025·0 cites·17 claims
- 2657US2019086386A1USE OF CERAMIDES AND LPLs IN DIAGNOSING CVDZORA BIOSCIENCES OY·Filed 2018·Application pending·0 cites
- 2755US9841431B2Lipidomic biomarkers for identification of high-risk coronary artery disease patientsZORA BIOSCIENCES OY·Filed 2015·Granted Dec 12, 2017·0 cites·22 claims
- 2855US2017082644A1Biomarkers for sensitive detection of statin-induced muscle toxicityZORA BIOSCIENCES OY·Filed 2016·Application pending·0 cites
- 2954US9459264B2Lipidomic biomarkers for atherosclerosis and cardiovascular diseaseZORA BIOSCIENCES OY·Filed 2015·Granted Oct 4, 2016·0 cites·29 claims
- 3054US5464314ADevice for handling a vehicle wheelAUTO JURE OY·Filed 1992·Granted Nov 7, 1995·18 cites·15 claims
- 3153US7611902B2Diagnostic method for myopathyZORA BIOSCIENCES OY·Filed 2007·Granted Nov 3, 2009·3 cites·11 claims
- 3252US10184932B2Use of ceramides and LPLs in diagnosing CVDZORA BIOSCIENCES OY·Filed 2016·Granted Jan 22, 2019·0 cites·3 claims
- 3350US9459265B2Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatmentZORA BIOSCIENCES OY·Filed 2015·Granted Oct 4, 2016·0 cites·21 claims
- 3450US2016363602A1Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatmentZORA BIOSCIENCES OY·Filed 2016·Application pending·0 cites
- 3548US2016018423A1Non-high density lipoprotein derived cvd markersZORA BIOSCIENCES OY·Filed 2014·Application pending·0 cites
- 3647US2016146842A2Sensitive Efficacy and Specificity Biomarkers for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) InhibitionZORA BIOSCIENCES OY·Filed 2013·Application pending·0 cites
- 3731US2004214264A1Nucleic acid molecule encoding a variant DDAH 1 protein and uses thereofFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Reijo Laaksonen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →